CAS 14233-48-8: 1,3,4,5-Tetra-O-benzyl-D-glucitol

2,3,4,6 -Tetra-O-benzyl-D-glucitol is an atypical compound with a spectrum of activities. It has been shown to inhibit the synthesis of alditols and aldosides in vitro, and it also inhibits miglustat which is the first drug for Gaucher's disease approved by the FDA. 2,3,4,6 -Tetra-O-benzyl-D-glucitol is synthetically produced from D-glucose and benzyl chloride. The compound crystallizes as a chiral form that can exist as either (S) or (R) conformation. The (S) form has been observed to be more active than the (R) form against showdomycin and cyclic peptidase A.